Strs Ohio Purchases Shares of 141,900 Puma Biotechnology, Inc. $PBYI

Key Points

• Strs Ohio acquired 141,900 shares of Puma Biotechnology, Inc. for approximately $420,000, representing about 0.29% ownership of the company.
• Puma Biotechnology received a rating upgrade from a "buy" to a "strong-buy" by Wall Street Zen, with a consensus price target of $7.00.
• Insiders have sold a total of 81,989 shares of Puma Biotechnology over the last 90 days, indicating significant activity among company leadership.

Strs Ohio bought a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 141,900 shares of the biopharmaceutical company's stock, valued at approximately $420,000. Strs Ohio owned approximately 0.29% of Puma Biotechnology as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in PBYI. ProShare Advisors LLC bought a new position in Puma Biotechnology during the 4th quarter valued at approximately $36,000. Causeway Capital Management LLC bought a new position in Puma Biotechnology during the 1st quarter valued at approximately $42,000. PFG Investments LLC bought a new position in Puma Biotechnology during the 1st quarter valued at approximately $59,000. Hsbc Holdings PLC bought a new position in Puma Biotechnology during the 1st quarter valued at approximately $61,000. Finally, Russell Investments Group Ltd. increased its position in Puma Biotechnology by 104,365.0% during the 1st quarter. Russell Investments Group Ltd. now owns 20,893 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 20,873 shares in the last quarter. Institutional investors own 61.29% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $7.00.

Puma Biotechnology Stock Performance

PBYI stock opened at $4.46 on Tuesday. The company has a market cap of $224.65 million, a P/E ratio of 4.55 and a beta of 1.37. Puma Biotechnology, Inc. has a 1 year low of $2.32 and a 1 year high of $6.07. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62. The stock's fifty day moving average price is $4.31 and its 200-day moving average price is $3.61.

Insiders Place Their Bets

In other news, Director Alessandra Cesano sold 27,000 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $3.37, for a total value of $90,990.00. Following the transaction, the director directly owned 41,850 shares in the company, valued at $141,034.50. This trade represents a 39.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Alan H. Auerbach sold 25,592 shares of the firm's stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total value of $90,339.76. Following the completion of the transaction, the chief executive officer owned 7,202,481 shares in the company, valued at approximately $25,424,757.93. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,989 shares of company stock worth $285,351. Company insiders own 23.30% of the company's stock.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.